Q-omics provides the consensus-scored ANGPTL6 profile across patient tissues and cancer cell-line models. ANGPTL6 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ANGPTL6 is differentially expressed in 8, with the highest sampling consensus in HNSC. Additionally, ANGPTL6 RNA expression shows 15,686 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, HNSC, and TGCT as cancer lineages where ANGPTL6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANGPTL6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANGPTL6 survival associations across molecular data types. ANGPTL6 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANGPTL6 RNA expression–survival associations across cancer types. High ANGPTL6 expression shows unfavorable associations in KIRC, LGG and KIRP, but favorable associations in CESC, HNSC and LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ANGPTL6 RNA expression.
This table summarizes ANGPTL6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ANGPTL6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANGPTL6 shows lower tumor expression in LIHC, KICH and KIRC and higher tumor expression in HNSC, THCA and BRCA. The HNSC box plot shows higher ANGPTL6 RNA expression in tumor versus normal tissue (log2 FC = +0.371, t-test p < 0.001).
This table shows molecular features associated with ANGPTL6 in patient tissues and cancer cell lines. In patient samples, ANGPTL6 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, ANGPTL6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and SKIN.
